AAD 2019 Archives - Medical Conferences

Home > Dermatology > AAD 2019

American Academy of Dermatology

1–5 March 2019 Washington DC, USA

Letter from the Editor

Editor

Prof. Peter CM van de Kerkhof, Radboud University Nijmegen Medical Centre, the Netherlands

Interview with AAD president Prof. George J. Hruza

Expert

Prof. George J. Hruza, Laser & Dermatologic Surgery Center, St Louis, USA

Late-Breakers

Secukinumab maintains improvements in psoriasis through 5 years of treatment

Presented By

Prof. Richard Langley, Dalhousie University, Canada

Bermekimab – a future treatment for atopic dermatitis?

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

JAK1/2 inhibitor effective in alopecia areata

Presented By

James Cassella, Concert Pharmaceuticals, USA

Novel anti-IgE drug enables durable urticaria control

Presented By

Dr Diane Baker, Baker Allergy, Asthma, and Dermatology Clinic, USA

Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, USA

Thicker AK lesions benefit from laser pretreatment with high channel density

Presented By

Dr Yeo-Rye Cho, Dong-A University Busan, Korea

New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials

Presented By

Prof. Lawrence Eichenfield, University of California, San Diego School of Medicine and Rady´s Children´s Hospital, USA

Increased cancer risk for patients with keloids

Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris

Presented By

Prof. Dedee Murrell, University of New South Wales, Australia

Serlopitant reduces pruritus associated with psoriasis

Presented By

Dr David Pariser, Pariser Dermatology Specialists Virginia, USA

Atopic Dermatitis: Many New Therapies in the Pipeline

New and emerging atopic dermatitis therapies

Presented By

Prof. David Cohen, New York University School of Medicine, USA

Food triggers eczema – an imperturbable belief of patients

Presented By

Dr Peter Lio, Northwestern University Chicago, USA

Psoriasis and Biologics: The Beat Goes On

Presented By

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA

JAK Inhibitors: A New Frontier in Dermatology

JAK inhibitors: a new therapeutic tool for dermatologists

Presented By

Prof. Brett King, Yale School of Medicine, USA

JAK inhibitors: a pathogenesis-directed therapy for alopecia areata

Presented By

Prof. Brittany Craiglow, Yale University School of Medicine, USA

Can JAK inhibitors close the current therapeutic gap in AD?

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Hair Loss: No Reason for Therapeutic Nihilism

Presented By

Dr Glynis Ablon, Dr Melissa Piliang, Prof. Antonella Tosti, Dr Jeff Donovan

Vitiligo: The Beginning of a New Era

Vitiligo in children

Presented By

Prof. Pearl Grimes, Vitiligo & Pigmentation Institute of Southern California, USA

Surgical treatment for selected vitiligo cases

Presented By

Dr Iltefat Hamzavi, Henry Ford Hospital, USA

JAK-inhibitors: an emerging treatment option for vitiligo

Presented By

Prof. John Harris, University of Massachusetts, USA

What's New and Hot in Acne

Oral antibiotics for acne treatment

Presented By

Dr Neal Bhatia, Therapeutics Clinical research, USA

Should we use more hormonal therapy?

Presented By

Dr Julie Claire Harper, Dermatology & Skin Care Center, USA

Pearls of the Posters

Plaque psoriasis – Efficacy of guselkumab

Pemphigus patients prone to osteoporosis

Presented By

Dr Raj Chovatiya, Northwestern University Feinberg School of Medicine, USA

Tralokinumab improves eczema and reduces staphylococcus aureus colonisation in AD

Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma

Presented By

Dr Emma Guttman-Yassky, Mount Sinai School of Medicine, USA

Medical Conferences

AAD 2019

Table of Contents

Featured articles

Letter from the Editor

Interview with AAD president Prof. George J. Hruza

Late-Breakers

Secukinumab maintains improvements in psoriasis through 5 years of treatment

Bermekimab – a future treatment for atopic dermatitis?

JAK1/2 inhibitor effective in alopecia areata

Novel anti-IgE drug enables durable urticaria control

Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis

Thicker AK lesions benefit from laser pretreatment with high channel density

New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials

Increased cancer risk for patients with keloids

Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris

Serlopitant reduces pruritus associated with psoriasis

Atopic Dermatitis: Many New Therapies in the Pipeline

New and emerging atopic dermatitis therapies

Food triggers eczema – an imperturbable belief of patients

Psoriasis and Biologics: The Beat Goes On

Psoriasis and Biologics: The Beat Goes On

JAK Inhibitors: A New Frontier in Dermatology

JAK inhibitors: a new therapeutic tool for dermatologists

JAK inhibitors: a pathogenesis-directed therapy for alopecia areata

Can JAK inhibitors close the current therapeutic gap in AD?

Hair Loss: No Reason for Therapeutic Nihilism

Hair Loss: No Reason for Therapeutic Nihilism

Vitiligo: The Beginning of a New Era

Vitiligo in children

Surgical treatment for selected vitiligo cases

JAK-inhibitors: an emerging treatment option for vitiligo

What's New and Hot in Acne

Oral antibiotics for acne treatment

Should we use more hormonal therapy?

Pearls of the Posters

Plaque psoriasis – Efficacy of guselkumab

Pemphigus patients prone to osteoporosis

Tralokinumab improves eczema and reduces staphylococcus aureus colonisation in AD

Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma